


Investment Strategy Update #50


Invest for Reflation not Inflation - Our strategy for 2Q21 and beyond

- Reflation, not inflation should remain the dominant investment theme throughout 2021. We recommend positioning for cyclical upside and hedging against inflation. We don't think it is too late to buy into the equity rally but some protection against near term downside risks seems prudent.
- Rising bond yields will continue to drive bouts of financial market volatility but are unlikely to undermine either the economic recovery or the equity bull market in the absence of a reversal in central bank policy support, which is not imminent.
- Equity markets are within a few percent of highs despite the rapid rise in bond yields. This does make them susceptible to tactical disappointment particularly given how fast *"value"* stocks have rallied back over the past six months. However, equities still provide a substantial yield premium to either cash or fixed income and further economic improvement underpins a positive medium-term outlook.
- Investors can help protect against downside risks by allocating to both value and growth stocks / markets as well as via real assets (commodities, property, infrastructure) and alternative assets (long/short, macro and relative value).
- We see any rates- driven volatility as an opportunity to add to risk asset exposure whether in growth or value stocks and/or markets. The cycle is rolling on and while uncertainty is rising, we expect reflation and rotation to remain dominant in positioning and relative performance.

As we move into 2Q21, we reiterate our strategy and discuss how we want to be positioned as we head further into the year. We entered 2021 focused on three key investment themes: 1) Reflation and the reopening of economies; 2) A gradual rise in bond yields; and 3) Rotation into more economically sensitive stocks vis-à-vis structural growth and COVID-19 winners. Implementing these views meant we had a pro-risk asset allocation tilt via a maximum overweight in equities and being underweight both cash and fixed income in order to take advantage of the reflation/rotation trade.



We don't see strong reasons to alter our key investment themes and recommend investors remain positioned for further cyclical upside as vaccination rates improve, fiscal and monetary stimulus remains in place, excess savings are deployed and the release of pent up demand provides a strong springboard for recovery (albeit at different speeds depending on COVID-19 progress). While inflation expectations have started to rise, they are only back in-line with average levels seen over the past 20+ years and we see this as a normalization from depressed and overly pessimistic levels. At this stage, there is no conclusive evidence that suggests we will see a sustained inflation increase and/or that structural headwinds that limited broad price increases in recent years have dissipated to an extent that we want to now position for a regime change.




Consequently, if inflation remains reasonably well behaved and central banks stay committed to easy monetary conditions (via yield curve control as well as anchoring short rates), then we don't think bond yields will rise to levels that undermine the global economic recovery nor the equity bull market.



Historically, equity markets have performed strongly during both the recovery and expansion phases of the economic cycle – despite the latter phase being accompanied by rising rates. Markets will not be oblivious to the threat of higher bond yields, particularly given the tailwind they have provided for valuations in recent years. Similarly, we have already seen that volatility driven by the bond market can be disruptive for parts of the equity complex - even if the overall market remains relatively insulated.

We think rising yields will continue to act as a headwind for high multiple growth stocks (particularly those which have been COVID-19 beneficiaries), but expect this to drive further rotation from growth stocks to value stocks and/or financials rather than driving a broad or sustained market correction. As outlined in "Investment Strategy Update #44 – Why it will take more than rising yields to kill the bull market", it is likely that rising bond yields will need to be accompanied by a number of other factors such as a reversal of easy monetary policy or deteriorating fundamentals if markets were to permanently reverse course.



It is too early to know whether the rotation in equity market leadership (from structural growth stocks to economically sensitive value stocks) will be a shortterm trade or develop into something more sustainable. However, in order for a regime shift to occur, economies must break out of the secular stagnation environment they have been in since the end of the global financial crisis and it is too early to tell whether this will be the case.

To an extent, we think it is a moot point as we don't believe it determines the amount of value stock exposure in a portfolio, but rather how long you hold that allocation (ie. if the cyclical recovery is more durable then we maintain our value exposure for longer rather than increasing it in an equity allocation sense). We don't think it is too late to buy the rally. We remind investors that it is time in the market rather than timing the market that will ultimately provide long term wealth creation. Markets might be expensive, they might have rallied hard from the lows and expectations around cyclical upside are well known. But we think policy makers are intent on pushing the recovery through to self-sustaining levels and this means further gains in corporate earnings as economies reopen and activity (spending on services) ramps higher.

If bond yields do not pressure valuations, then we expect equities remain the asset class of choice versus cash and fixed income as the reflation / rotation trade continues to dominate. This remains the case even though outperformance will likely moderate after a stunning six months where a lot of the valuation normalisation has already occurred. For the income inclined, we think equities will continue to offer a substantial yield premium to bonds for the foreseeable future.



While we don't think it is too late to buy into the market, we do think it is important to have some protection against downside risks taken within and across asset classes. Within equities, we recommend investors have a mix of both value and growth stock/market exposure which allows leverage into reflation, but also a hedge against this trade reversing or running its course earlier than expected. Ultimately, we prefer investors focus on "valuation" rather than a "value" or "growth", but tactically we do expect value to continue outperforming growth. In addition, a gradual increase in long bond yields will drive further yield curve steeping and this should provide ongoing performance support for banks and diversified financials (see "Investment Strategy Update #30 – Australian Banks the start of a new beginning").



The recent rebound in growth stocks suggest that investors are not prepared to abandon these names despite the potential for the reflation trade to strengthen. We think this is the right assessment of the backdrop where in the absence of a sustained rise in inflation, bond yield upside will be capped by any resulting equity market weakness (and tightening in financial conditions).

As a result, investors should stay overweight equities, and should use bouts of volatility to raise exposure to structural growth stocks that might be under selling pressure from higher bond yields. We recommend holding both real assets (commodities, property and infrastructure) which should both benefit from cyclical upside, rising inflation and easy liquidity conditions while also raising exposure to alternative assets (long/short equities, relative value) that have limited exposure to the direction of interest rates and/or equity markets.

Macquarie WM Investment Strategy

The report was finalised on 29 March 2021.

Recommendation definitions (Macquarie Australia/New Zealand)

Outperform - return >3% in excess of benchmark return

Neutral - return within 3% of benchmark return

Underperform - return >3% below benchmark return

The analyst(s) responsible for the preparation of this research receives compensation based on overall revenues of Macquarie Group Limited (ABN 94 122 169 279 AFSL 318062) ("MGL") and its related entities (the "Macquarie Group", "MGL", "We" or "Us"). No part of the compensation of the analyst(s) was, is or will be directly or indirectly related to the inclusion of specific recommendations or views in this research.

This research has been issued and is distributed in Australia by Macquarie Equities Limited (ABN 41 002 574 923 AFSL 237504) ("MEL" or "We"), a Participant of the ASX. MEL is not an authorised deposit-taking institution for the purposes of the Banking Act 1959 (Cth), and MEL's obligations do not represent deposits or other liabilities of Macquarie Bank Limited (ABN 46 008 583 542). Macquarie Bank Limited does not guarantee or otherwise provide assurance in respect of the obligations of MEL.

This research contains general advice and does not take account of your objectives, financial situation or needs. Before acting on this general advice, you should consider if it is appropriate for you. We recommend you obtain financial, legal and taxation advice before making any financial investment decision. Past performance is not a reliable indicator of future performance. You should consider all factors and risks before making a decision. Please refer to MEL's Financial Services Guide (FSG) for more information at https://www.macquarie.com.au/advisers/financial-services-guide.html.

This research has been prepared for the use of the clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient, you must not use or disclose this research in any way. If you received it in error, please tell us immediately by return e -mail and delete the document. We do not guarantee the integrity of any links, e-mails or attached files and are not responsible for any changes made to them by any other person. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. This research is based on information obtained from sources believed to be reliable, but We do not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. We accept no liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. The Macquarie Group produces a variety of research products, recommendations contained in one type of research product may differ from recommendations contained in other types of research.

The Macquarie Group has established and implemented a conflicts policy at group level, which may be revised and updated from time to time, pursuant to regulatory requirements, which sets out how we must seek to identify and manage all material conflicts of interest. The Macquarie Group, its officers and employees may have conflicting roles in the financial products referred to in this research and, as such, may affect transactions which are not consistent with the recommendations (if any) in this research. The Macquarie Group may receive fees, brokerage or commissions for acting in those capacities and the reader should assume that this is the case. The Macquarie Group's employees or officers may provide oral or written opinions to its clients which are contrary to the opinions expressed in this research.

Important disclosure information regarding the subject companies covered in this report is available at macquarie.com/disclosures.